开设账户
模拟账户
关于我们
即时报价及新闻
市场分析
财经日历
每日市场分析
交易平台
下载及介绍
使用教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
繁
简
EN
客户登入
开设账户
模拟账户
繁
简
EN
客户登入
开设账户
模拟账户
关于我们
上志国际介绍
上志国际优势
即时报价及新闻
即时报价
即时新闻
市场分析
财经日历
市场分析
交易平台
平台特点
平台教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
关于我们
交易细则
贵金属市场
交易平台
市场分析
推广和资讯
常见问题
联络我们
繁
简
EN
SHFE silver main futures contract plunged 6.00% intraday, trading at 12,141.00 yuan/kg.
2026-10-30
SHFE silver main futures contract plunged 6.00% intraday, trading at 12,141.00 yuan/kg.
返回
其他消息
2026-10-29
壳牌首席执行官:现金流激增不会削弱支出纪律。
壳牌首席执行官:现金流激增不会削弱支出纪律。
2026-10-29
Eli Lilly (LLY.N) raised 2026 full-year sales guidance to $91–92bn from $85–87bn. The company said acquisition-related effects leave expected adjusted EPS at $35–36 for the year, slightly below prior guidance. Q3 2026 revenue was $24.4bn, beating the Street consensus of $22.5bn. Diabetes drug Mounjaro generated $10.7bn in sales and weight‑loss drug Zepbound $5.35bn, both above analysts’ estimates. Management also reported progress on regulatory approvals for its products. Shares were up more tha
Eli Lilly (LLY.N) raised 2026 full-year sales guidance to $91–92bn from $85–87bn. The company said acquisition-related effects leave expected adjusted EPS at $35–36 for the year, slightly below prior guidance. Q3 2026 revenue was $24.4bn, beating the Street consensus of $22.5bn. Diabetes drug Mounjaro generated $10.7bn in sales and weight‑loss drug Zepbound $5.35bn, both above analysts’ estimates. Management also reported progress on regulatory approvals for its products. Shares were up more than 4% premarket; the stock is up nearly 20% year‑to‑date through Wednesday’s close.
Chat with us
, powered by
LiveChat